The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders.

Cruz Rivera, Samantha, McMullan, Christel, Jones, Laura, Kyte, Derek, Slade, Anita and Calvert, Melanie J (2020) The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. Journal of patient-reported outcomes, 4 (1). p. 51. ISSN 2509-8020. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

[img] Text (PDF file format)
s41687-020-00219-4 - Published Version
Available under License Creative Commons Attribution 4.0.

Download (1MB)
Official URL: https://jpro.springeropen.com/

Abstract

BACKGROUND

Patient-reported outcomes (PROs) are increasingly collected in clinical trials as they provide unique information on the physical, functional and psychological impact of a treatment from the patient's perspective. Recent research suggests that PRO trial data have the potential to inform shared decision-making, support pharmaceutical labelling claims and influence healthcare policy and practice. However, there remains limited evidence regarding the actual impact associated with PRO trial data and how to maximise PRO impact to benefit patients and society. Thus, our objective was to qualitatively explore international stakeholders' perspectives surrounding: a) the impact of PRO trial data, b) impact measurement metrics, and c) barriers and facilitators to effectively maximise the impact of PRO trial data upon patients and society.

METHODS

Semi-structured interviews with 24 international stakeholders were conducted between May and October 2018. Data were coded and analysed using reflexive thematic analysis.

RESULTS

International stakeholders emphasised the impact of PRO trial data to benefit patients and society. Influence on policy-impact, including changes to clinical healthcare practice and guidelines, drug approval and promotional labelling claims were common types of PRO impact reported by interviewees. Interviewees suggested impact measurement metrics including: number of pharmaceutical labelling claims and interviews with healthcare practitioners to determine whether PRO data were incorporated in clinical decision-making. Key facilitators to PRO impact highlighted by stakeholders included: standardisation of PRO tools; consideration of health utilities when selecting PRO measures; adequate funding to support PRO research; improved reporting and dissemination of PRO trial data by key opinion leaders and patients; and development of legal enforcement of the collection of PRO data.

CONCLUSIONS

Determining the impact of PRO trial data is essential to better allocate funds, minimise research waste and to help maximise the impact of these data for patients and society. However, measuring the impact of PRO trial data through metrics is a challenging task, as current measures do not capture the total impact of PRO research. Broader international multi-stakeholder engagement and collaboration is needed to standardise PRO assessment and maximise the impact of PRO trial data to benefit patients and society.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QW Microbiology. Immunology
W Public health. Health statistics. Occupational health. Health education
WA Patients. Primary care. Medical profession. Forensic medicine
Divisions: Ambulatory Care > Outpatients
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 15 Jul 2020 10:46
Last Modified: 15 Jul 2020 10:46
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3271

Actions (login required)

View Item View Item